This site is for U.S. Healthcare Professionals only.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Poster
Valemetostat
SOHO 2024 Annual Meeting | September 4-7, 2024
A phase 1 trial of valemetostat in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL)
Poster
DS-1471
ESMO 2024 | September 13-17, 2024
A phase 1, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors
Poster
Other/Multi
ASCO 2025 | May 30-June 3,2025
A phase 1, first-in-human study of DS-2243, an HLA-A*02/NY-ESO–directed bispecific T‑cell engager, in patients with advanced solid tumors
Poster
T-DXd
ESMO Asia 2024 | December 6-8, 2024
An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2
Poster
T-DXd
AACR 2025 | April 25-29, 2025
Baseline serum protein analysis of patients with interstitial lung disease/pneumonitis (ILD) in 3 trastuzumab deruxtecan (T-DXd) trials: DESTINY-Breast01, DESTINY-Breast04, and DESTINY-Lung01
Poster
Other/Multi
ESMO 2024 | September 13-17, 2024
Claudin-6 expression in primary and recurrant epithelial ovarian cancer: A potential therapeutic target for high-grade serous ovarian cancer
Poster
I-DXd
ACCP 2024 | September 8-10, 2024
Concentration-QTc interim analysis of I-DXd in subjects with advanced solid tumors from study IDeate-PanTumor01 (DS7300-A-J101)
Mini-Oral
Dato-DXd
ESMO 2024 | September 13-17, 2024
Datopotamab deruxtecan (Dato-DXd) in patients with ovarian or endometrial cancer: Results from the phase 2 TROPION-PanTumor03 study
Poster
Valemetostat
ASCPT 2025 | May 28-31, 2025
Effect of valemetostat on the pharmacokinetics of midazolam and digoxin (CYP3A and P-gp substrates): A phase 1 drug–drug interaction study in patients with refractory or relapsed non-hodgkin lymphoma
Poster
T-DXd
ESMO 2024 | September 13-17, 2024
HER2 testing in multiple solid tumors: Concordance between 3 scoring algorithms